The impact of p16 and HER2 expression on survival in patients with ovarian carcinoma

Shandiz, F. H. and Kadkhodayan, S. and Ghaffarzadegan, K. and Esmaeily, H. and Torabi, S. and Khales, S. A. (2016) The impact of p16 and HER2 expression on survival in patients with ovarian carcinoma. Neoplasma, 63 (5). pp. 816-821.

[img] Text

Download (423kB)


The purpose of this study was to investigate the impact of p16 and HER2 expression on survival in patients with ovarian carcinoma. Th is descriptive-analytic,cross-sectional study,was conducted on 47 paraffi n blocks of epithelial ovarian tumors. Suitable slides were prepared to evaluate HER2 and p16 by immunohistochemistry using HercepTest kit (DAKO) and p16INK4A kit (DAKO,code 5334). Clinical information and pathology data were extracted from patients’ medical and pathology records. Data entry and analysis was done by SPSS (version 16) soft ware. Chi-square test,Mann-Whitney test,t-test,Kruskal-Wallis test,log rank test and Kaplan-Meier method were used. Th e mean age of the patients was 51.6 years (range 19-71 years). Th e most common histological type of epithelial ovarian cancer was serous adenocarcinoma (68.1). P16 expression was detected in 34 of epithelial ovarian tumors. P16 expression was signifi cantly associated with stage of disease (P = 0.04) and overall survival (P = 0.001),but HER2 expression was not associated with overall survival,stage of disease and tumor histological type. Expression of p16 may be used as a prognostic factor of overall survival and stage of disease,while HER2 expression may not be used as a prognostic factor of overall survival. © 2016,Cancer Research Institute Slovak Acad. of Sciences. All rights reserved.

Item Type: Article
Additional Information: Cited By :3 Export Date: 16 February 2020 CODEN: NEOLA Correspondence Address: Khales, S.A.; Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical SciencesIran; email:
Uncontrolled Keywords: Epithelial ovarian tumors HER2/neu Immunohistochemistry p16 epidermal growth factor receptor 2 protein p16 cyclin dependent kinase inhibitor 2A ERBB2 protein, human P16 protein, human tumor marker adenocarcinoma adult aged Article cancer survival clear cell carcinoma cross-sectional study endometrioid carcinoma female follow up human human tissue ovary carcinoma protein expression biosynthesis cystadenocarcinoma genetics metabolism middle aged mortality ovary tumor pathology prognosis young adult Biomarkers, Tumor Cyclin-Dependent Kinase Inhibitor p16 Cystadenocarcinoma, Serous Humans Ovarian Neoplasms Receptor, ErbB-2
Subjects: WP Gynecology
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib4 lib4
Date Deposited: 26 Feb 2020 09:25
Last Modified: 26 Feb 2020 09:25

Actions (login required)

View Item View Item